CureVac initiated with a Not Rated at Goldman Sachs

Goldman Sachs initiated coverage of CureVac with a Not Rated and no price target. The company has a pipeline that includes assets across multiple therapeutic areas including prophylactic infectious disease vaccines, oncology and molecular therapies, the analyst tells investors in a research note. The firm sees CureVac’s “optionality as interesting albeit early” and is awaiting a partner to fully unlock its clinical and commercial potential.